We showed that lifelong exposure to the DYRK1A inhibitors had no detectable effect on lifespan of control, however they were found to be effective at suppressing the shortening of life caused by pan-neuronal overexpression of AD-associated Tau and Aβ42. This evidence concerns the gene MAPT and Alzheimer disease.